Deals

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million
ADC / XDCClearideBio Therapeutics

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million

Shanghai MicuRx Pharmaceuticals, Inc. (SHA: 688373) announced that it intends to enter into an MRX‑23 License Agreement and a Platform Technology Cooperation Agreement with ClearideBio Therapeutics AG, a Switzerland‑based biopharmaceutical…

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
COVID-19NASDAQ: SNY

Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion

BioNTechBiotheus

BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody

IPOMirxes

Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO

DiabetesObesity

Tonghua Dongbao Pharmaceuticals Inks Licensing Deal for Semaglutide in China

Show More